Jupiter Topco LLC Makes New Investment in DexCom, Inc. $DXCM

Jupiter Topco LLC purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 1,138,783 shares of the medical device company’s stock, valued at approximately $76,696,000.

Other large investors have also made changes to their positions in the company. BOKF NA raised its position in shares of DexCom by 175.7% during the fourth quarter. BOKF NA now owns 35,314 shares of the medical device company’s stock valued at $2,344,000 after buying an additional 22,505 shares during the last quarter. Plato Investment Management Ltd purchased a new position in shares of DexCom in the second quarter worth $782,000. Stephens Investment Management Group LLC boosted its position in shares of DexCom by 21.1% during the fourth quarter. Stephens Investment Management Group LLC now owns 1,042,801 shares of the medical device company’s stock worth $69,211,000 after acquiring an additional 181,701 shares during the last quarter. Eurizon Capital SGR S.p.A. bought a new position in shares of DexCom during the fourth quarter worth $3,231,000. Finally, Goodman Advisory Group LLC purchased a new position in DexCom during the fourth quarter valued at $1,293,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other DexCom news, insider Kevin R. Sayer sold 26,756 shares of the firm’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $76.32, for a total value of $2,042,017.92. Following the completion of the sale, the insider owned 328,970 shares of the company’s stock, valued at $25,106,990.40. This trade represents a 7.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $85.32, for a total value of $170,640.00. Following the transaction, the director owned 48,852 shares of the company’s stock, valued at $4,168,052.64. This trade represents a 3.93% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 73,035 shares of company stock valued at $5,446,673. Company insiders own 0.28% of the company’s stock.

DexCom Trading Up 0.4%

DXCM stock opened at $89.29 on Friday. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $92.59. The stock has a market capitalization of $33.69 billion, a price-to-earnings ratio of 35.29, a price-to-earnings-growth ratio of 1.50 and a beta of 1.41. The firm’s fifty day simple moving average is $78.84 and its two-hundred day simple moving average is $71.47.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same quarter last year, the business earned $0.48 EPS. The business’s revenue was up 13.1% on a year-over-year basis. As a group, analysts anticipate that DexCom, Inc. will post 2.64 earnings per share for the current year.

Analysts Set New Price Targets

DXCM has been the topic of a number of research reports. Stifel Nicolaus set a $95.00 price target on shares of DexCom and gave the company a “buy” rating in a report on Friday, July 31st. Citigroup reissued a “buy” rating and set a $88.00 price objective (up from $84.00) on shares of DexCom in a report on Friday, July 31st. Bank of America cut their price objective on DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Truist Financial set a $93.00 target price on DexCom and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Weiss Ratings upgraded DexCom from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $88.71.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.